"Severe myoclonic epilepsy in infancy" relevance for the clinician of severe epilepsy starting in infancy

Acta Neurologica Belgica

Volumn 104, Issue 3, 2004, Pages 95-99

  Ceulemans, Berten ^a,b,c   Cras, Patrick ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Epilepsy Centre for Children/Youth   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Dravet syndrome; SCN1A; Severe epilepsy; SMEI; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; BROMIDE; CARBAMAZEPINE; CLOBAZAM; CORTICOSTEROID; DIAZEPAM; DNA; ETHOSUXIMIDE; IMMUNOGLOBULIN; LAMOTRIGINE; LORAZEPAM; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; PIRACETAM; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; STIRIPENTOL; TOPIRAMATE; VALPROIC ACID;

ACUTE DISEASE; ALPHA CHAIN; CHILD DEVELOPMENT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE SEVERITY; DNA DETERMINATION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG MECHANISM; EPILEPTIC STATE; FEBRILE CONVULSION; FOLLOW UP; GENE MUTATION; HUMAN; INFANCY; KETOGENIC DIET; LONG TERM CARE; MENTAL DEFICIENCY; MYOCLONUS EPILEPSY; NERVE CELL; NEUROSURGERY; ONSET AGE; QUALITY OF LIFE; REVIEW; SEIZURE;

EID: 5144225065     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Campos Castello J. Therapeutic strategy in severe encephalopathies. Rev. Neurol., 2001, 32 (9) : 864866.
2. Ceulemans B., Claes L., Lagae L. Clinical correlations of mutations in the SCN1A gene : from FS to SMEI. Ped. Neurology, 2004, 30 (4) : 236-243.
3. Ceulemans B., Boel M., Claes L., Dom L., Willekens H. et al. Severe myoclonic epilepsy in infancy : towards an optimal treatment. J. Child Neurol. (Accepted).
4. Chiron C., Marchand M.C., Tran A., Rey E., D'Athis P. et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet, 2000, 356 (9242) : 1638-42.
5. Claes L., Del-Favero J., Ceulemans B., Lagae L., Van Broeckhoven C. et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am. J. Hum. Genet., 2001, 68 (6) : 1327-32.
6. Claes L., Ceulemans B., Audenaert D., Smets K., Löfgren A. et al. De Novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy. Hum. Mut., 2003, 21 : 615-621.
7. Coppola G., Capovilla G., Montagnini A., Romeo A., Spano M. et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy : an Italian multicenter open trial. Epilepsy Res., 2002, 49 (1) : 45-48.
8. Dalla-Bernadina B., Calamaria V., Capovilla G., Bondavilli S. Nosological classification of epilepsies in the first three years of life. In : Epilepsy : an update on research and therapy. Nisitico G., Di Perri R., Meinardi H. (eds.). New York, Alan Liss, 1983, 165-183.
9. Dravet C. Les épilepsies graves de l'enfant. Vie Méd., 1978, 8 : 543-548.
10. Dravet C., Roger J., Bureau M., Dalla Bernardina B. Myoclonic epilepsies in childhood. In : Advances in Epileptology : XIIIth Epilepsy International Symposium. Akimoto H., Kasamatsuri H., Seino M., Ward A. New-York, Raven Press, 1982, 135-140.
11. Dravet C., Bureau M., Roger J. Severe myoclonic epilepsy in infants. In : Epileptic syndromes in infancy, childhood and adolescence. Roger J., Dravet C., Bureau M., Dreifuss F. E., Wolf P. (eds.). London, John Libbey, 1985, 58-67.
12. Dravet C., Bureau M., Oguni H., Fukuyama Y., Cokar O. Severe myoclonic epilepsy in infancy (Dravet syndrome). In: Epileptic Syndromes in infancy, childhood and adolescence. Roger J., Bureau M., Dravet C., Genton P., Tassinari C., Wolf P. (eds.), 2002, 81-103.
13. Engel J. ILAE Commission Report. Epilepsia, 2001, 42 (6) : 796-803.
14. Fişgin T., Gurer Y., Tezic T., Senbil N., Zorlu P. et al. Effects of Intranasal Midazolam and Rectal Diazepam on Acute Convulsions in Children : Prospective Randomized Study. J. Child Neurol., 2002, 17 (2) : 123-126.
15. Hurst D. L. Epidemiology of severe myoclonic epilepsy of infancy. Epilepsia, 1990, 31 (4) : 397-400.
16. Nabbout R., Gennaro E., Dalla Bernardina B., Dulac O., Madia F. et al. Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology, 2003, 60 : 1961-1967.
17. Nieto-Barrera M., Candau R., Nieto-Jimenez M., Correa A., del Portal L. R. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure, 2000, 9 (8) : 590-4.
18. Oguni H., Hayashi K., Awaya Y., Fukuyama Y., Osawa M. Severe myoclonic epilepsy in infants - a review based on the Tokyo Women's Medical University series of 84 cases. Brain Dev., 2001, 23 (7) : 736-48.
19. Ohmori I., Ouchida M., Ohtsuka Y., Oka E., Shimizu K. Significant correlation of the SCN1A mutations and severe myoclonic epilepsy in infancy. Biochemical and Biophysical Research Communications, 2002, 295 : 17-23.
20. Ohtsuka Y., Maniwa S., Ogino T., Yamatogi Y., Ohtahara S. Severe myoclonic epilepsy in infancy : a long-term follow-up study. Jpn. J. Psychiatry Neurol., 1991, 45 (2) : 416-8.
21. Sugawara T., Mazaki-Miyazaki E., Fukushima K., Shimomura J., Fujiwara T. et al. Frequent mutations of SCN1A in severe myoclonic epilepsy in infancy. Neurology, 2002, 58 : 1122-1124.
22. Yakoub M., Dulac O., Jambaque I., Chiron C., Plouin P. Early diagnosis of severe myoclonic epilepsy in infancy. Brain Dev., 1992, 14 (5) : 299-303.